Security
ONSIW · Outlook Therapeutics, Inc.
ONSIWNASDAQWarrantHistorical · closed Dec 3, 2024CIK 1649989Updated Sep 26, 2026
Name history
Oncobiologics, Inc. · through Nov 13, 2018
Current security for this SEC filerOTLK · NASDAQ
ONSIW price & chart
Historical security
This listing closed Dec 3, 2024. Live provider charts are shown only for current listings.
Current security: OTLK
About the company
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of LYTENAVA (bevacizumab-vikg (U.S.), bevacizumab gamma (E.U.)). LYTENAVA is the only ophthalmic formulation of bevacizumab to receive U.S. FDA approval and European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany, Austria, and the UK as a treatment for wet AMD.
In the news
No coverage from other publishers is available.
Recent filings
Other Events
Items 8.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
10-Q filing
NT 10-Q filing
4 filing
Show 5 more recent filings
Other Events
Items 8.01, 9.01
424B5 filing
Results of Operations and Financial Condition
Items 2.02, 9.01
424B5 filing
Results of Operations and Financial Condition · Other Events
Items 2.02, 8.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 18,584,183Source | 28,823,154Source | 32,300,601Source | 28,527,751Source |
| Property, Plant and Equipment | — | — | — | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 8,083,085Source | 14,927,538Source | 23,391,982Source | 17,396,812Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 1,490,931Source | — | — | — |
| Inventory, NetUSD | 3,338,404Source | — | — | — |
| Assets, CurrentUSD | 17,388,969Source | 27,416,036Source | 30,979,198Source | 27,520,446Source |
| Prepaid Expense and Other Assets, CurrentUSD | 4,476,549Source | 12,488,498Source | 7,587,216Source | 10,123,634Source |
| Operating Lease, Right-of-Use AssetUSD | 225,508Source | 274,645Source | 26,172Source | 70,360Source |
| Other Assets, NoncurrentUSD | 417,523Source | 439,283Source | 501,299Source | 132,015Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 50,771,844Source | 101,899,664Source | 46,738,378Source | 19,791,180Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 538,873Source | 239,057Source | 2,602,574Source | 2,273,105Source |
| Retained Earnings (Accumulated Deficit)USD | -605,709,763Source | -543,284,900Source | -467,918,186Source | -408,935,518Source |
| Stockholders' Equity Attributable to ParentUSD | -32,187,661Source | -73,076,510Source | -14,437,777Source | 8,736,571Source |
| Additional Paid in Capital, Common StockUSD | 572,983,229Source | 469,969,333Source | 450,877,835Source | 415,398,984Source |
| Liabilities and EquityUSD | 18,584,183Source | 28,823,154Source | 32,300,601Source | 28,527,751Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 45,814,605Source | 42,553,729Source | 46,732,159Source | 19,729,775Source |
| Operating Lease, Liability, CurrentUSD | 58,897Source | 50,907Source | — | 26,995Source |
| Accounts Payable, CurrentUSD | 10,192,388Source | 7,968,725Source | 6,574,523Source | 3,491,485Source |
| Operating Lease, Liability, NoncurrentUSD | 188,801Source | 246,922Source | — | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 5,314,320Source | 3,237,468Source | 2,745,740Source | 3,427,900Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 8,897,887Source | 5,385,124Source | 5,547,019Source | 7,710,804Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 1,490,931Source | — | — | — |
| Increase (Decrease) in InventoriesUSD | 3,338,404Source | — | — | — |
| Increase (Decrease) in Accounts PayableUSD | 1,666,049Source | 1,394,202Source | 3,083,038Source | 1,295,136Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -51,829,437Source | -68,793,858Source | -42,973,398Source | -56,674,559Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 44,984,984Source | 60,329,414Source | 48,968,568Source | 59,594,047Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -6,844,453Source | -8,464,444Source | 5,995,170Source | 2,919,488Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 8,083,085Source | 14,927,538Source | 23,391,982Source | 17,396,812Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | 475,000Source | 1,160,008Source | 1,556,691Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 8,859,896Source | 5,385,124Source | 5,547,019Source | 7,710,804Source |
| DepreciationUSD | — | — | — | 163,625Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | -577,659Source | -1,025,402Source |
| General and Administrative ExpenseUSD | — | 29,940,188Source | 26,673,440Source | 20,739,897Source |
| Income (Loss) from Equity Method InvestmentsUSD | -141,007Source | -100,742Source | -10,998Source | -48,730Source |
| Income Tax Expense (Benefit)USD | -1,551,829Source | 2,800Source | 2,800Source | 2,800Source |
| InterestExpenseNonoperatingUSD | — | 3,156,964Source | — | — |
| Investment Income, InterestUSD | 89,738Source | 906,150Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -62,424,863Source | -75,366,714Source | -58,982,668Source | -66,052,264Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -62,424,863Source | -75,366,714Source | -58,982,668Source | -66,052,264Source |
| Payments of Financing CostsUSD | — | — | 823,894Source | 600,000Source |
| Proceeds from Issuance of Common StockUSD | 25,396,398Source | 60,333,681Source | 30,024,213Source | 62,307,307Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | 17,750Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 1,413,535Source | — | — | — |
| Cost of RevenueUSD | 1,356,330Source | — | — | — |
| Selling, General and Administrative ExpenseUSD | 39,938,231Source | — | — | — |
| Operating Income (Loss)USD | -67,061,666Source | -71,703,235Source | -53,126,382Source | -63,070,753Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -63,976,692Source | -75,363,914Source | -58,979,868Source | -66,049,464Source |
| Income Tax Expense (Benefit)USD | -1,551,829Source | 2,800Source | 2,800Source | 2,800Source |
| Net Income (Loss) Attributable to ParentUSD | -62,424,863Source | -75,366,714Source | -58,982,668Source | -66,052,264Source |
| Earnings Per Share, BasicUSD per share | -1.79Source | -4.06Source | -0.24Source | -0.31Source |
| Earnings Per Share, DilutedUSD per share | -1.79Source | -4.06Source | -0.24Source | -0.31Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 34,796,120Source | 18,548,813Source | 250,176,633Source | 212,079,472Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 34,796,120Source | 18,548,813Source | 250,176,633Source | 212,079,472Source |
| Interest Expense (non-operating)USD | — | 3,156,964Source | — | — |
| Additional Financial Items | ||||
| Depreciation, Depletion and Amortization, NonproductionUSD | 117,052Source | 113,859Source | 44,188Source | 204,694Source |
| General and Administrative ExpenseUSD | — | 29,940,188Source | 26,673,440Source | 20,739,897Source |
| Gross ProfitUSD | 57,205Source | — | — | — |
| Income (Loss) from Equity Method InvestmentsUSD | -141,007Source | -100,742Source | -10,998Source | -48,730Source |
| Interest Income (Expense), NetUSD | -283,128Source | — | -1,559,748Source | -1,487,456Source |
| Investment Income, InterestUSD | 89,738Source | 906,150Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -62,424,863Source | -75,366,714Source | -58,982,668Source | -66,052,264Source |
| Research and Development ExpenseUSD | 27,180,640Source | 41,763,047Source | 26,452,942Source | 42,330,856Source |
Filing attachments
tm2622399d2_ex4-1.htm · 8-K · 2026-08-14
EX-4.1 3 tm2622399d2_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 FORM OF COMMON STOCK PURCHASE WARRANT OUTLOOK THERAPEUTICS, INC. Warrant Number: 2026-[●] Issue Date: August [●], 2026 ────────────────────────────────────────────────────────────── THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [●] or its permitted assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at …
Read attachment ↗tm2622399d3_ex99-1.htm · 8-K · 2026-08-14
EX-99.1 2 tm2622399d3_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™ The only FDA-approved ophthalmic bevacizumab, LYTENAVATM, addresses a significant need in the U.S. wet AMD market where bevacizumab is already widely used Advancing the U.S. launch strategy for LYTENAVA, including broad market access, reimbursement, pricing, medical affairs, and supply c…
Read attachment ↗tm2622278d1_ex99-1.htm · 8-K · 2026-08-12
EX-99.1 2 tm2622278d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Risk Factors You should consider carefully the risks and uncertainties described below. If any of the following risks are realized, our business, financial condition, results of operations, and prospects could be adversely affected. The risks described below are not the only risks facing our company. Risks and uncertainties not currently known to us or that we currently deem to be immaterial also may adversely affect our business, …
Read attachment ↗tm2621316d1_ex99-1.htm · 8-K · 2026-07-24
EX-99.1 2 tm2621316d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD Landmark FDA Approval Is an Important Milestone in Retina Care, Bringing Patients and Physicians an Ophthalmic Bevacizumab Developed Specifically for the Eye Following Years of Rigorous Clinical and Regulatory Evaluation Company Launches Commercial Franchise Positioned to Establish a New Stan…
Read attachment ↗tm2618010d1_ex99-1.htm · 8-K · 2026-06-16
EX-99.1 2 tm2618010d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD Prescription Drug User Fee Act (PDUFA) goal date of July 29, 2026 ISELIN, N.J., June 16, 2026 - Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today annou…
Read attachment ↗tm2616461d1_ex99-1.htm · 8-K · 2026-06-01
EX-99.1 2 tm2616461d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg) ISELIN, N.J., June 1, 2026 - Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced the resubmission of its Biologics Licens…
Read attachment ↗